Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening


CLDs represent an important, and certainly underestimated, global public health problem. CLDs are highly prevalent and silent, related to different, sometimes associated causes. The distribution of the causes of these diseases is slowly changing, and within the next decade, the proportion of virus‐induced CLDs will certainly decrease significantly while the proportion of NASH will increase. There is an urgent need for effective global actions including education, prevention and early diagnosis to manage and treat CLDs, thus preventing cirrhosis‐related morbidity and mortality. Our role is to increase the awareness of the public, healthcare professionals and public health authorities to encourage active policies for early management that will decrease the short‐ and long‐term public health burden of these diseases. Because necroinflammation is the key mechanism in the progression of CLDs, it should be detected early. Thus, large‐scale screening for CLDs is needed. ALT levels are an easy and inexpensive marker of liver necroinflammation and could be the first‐line tool in this process.


alcoholic liver disease, ALT, chronic liver disease, cirrhosis, epidemiology, hepatitis B, hepatitis C, hepatocellular carcinoma, NAFLD, NASH, screening


About Speaker



Institution: Hôpital Beaujon


Biography of Patrick MARCELLIN

Professor of Hepatology, University of Paris, Paris, France Patrick Marcellin is Professor of Hepatology at the University of Paris and Head of the Viral Hepatitis Research Unit in Hôpital Beaujon, Clichy. He earned his medical degree from the University of Paris and undertook postgraduate training in both internal medicine and gastroenterology-hepatology at the Assistance Publique-Hôpitaux de Paris. Professor Marcellin completed research fellowships in immunology (College of Physicians and Surgeons at Columbia University, New York City, USA) and virology (Institut Pasteur, Paris). He also holds a PhD in virology. Since 1984, he has been actively involved in laboratory and clinical research on viral hepatitis and liver diseases. His major focus has been on viral hepatitis therapy, and as such he has been the principal investigator on initial trials of first interferons and antivirals and on several pivotal studies investigating therapies for chronic hepatitis B and C. Professor Marcellin was a member of the Scientific Committee of EASL and organised the EASL Consensus Conference on Hepatitis C in 1999 and the EASL Consensus Conference on Hepatitis B in 2002. He was the Chairman of the panel on the 2009 EASL hepatitis B guidelines. He is the President of APHC that has organised the Annual Paris Hepatitis Conference for the last 10 years.

View more